Cardiomyopathy Clinical Trial
Official title:
Virtual Left Ventricular Lead Navigation in Patients With Ischemic Cardiomyopathy
Verified date | August 2015 |
Source | University of Pittsburgh |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Presently, the left ventricular lead is placed in a similar position for all patients. It is not known whether placing this lead in different positions in the heart will make the heart pump better. In this study, the investigator will collect measurements of the heart's electrical activity during an Electrophysiology Study (EP study or EPS). The hope is that these measurements will provide the know how to develop an individualized left ventricular lead placement "prescription" for patients referred for left ventricular lead pacing.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | October 2014 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Ischemic cardiomyopathy - Intrinsic QRS duration >120 milliseconds - LV ejection fraction <40% Exclusion Criteria: - Persistent atrial tachyarrhythmia - Active cardiac ischemia - Cerebrovascular accident within 6 months - Surgical or percutaneous cardiac revascularization procedure within 3 months - Under 18 years of age - Pregnant - Participating in a clinical study that would preclude enrollment - Unable to provide informed consent |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
United States | UPMC Presbyterian Hospital | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pittsburgh | Medtronic |
United States,
Adelstein EC, Saba S. Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy. Am Heart J. 2007 Jan;153(1):105-12. — View Citation
Barold SS, Herwerg B. Pacing in heart failure: how many leads and where? Heart. 2008 Jan;94(1):10-2. — View Citation
Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000 Mar 1;35(3):569-82. Review. — View Citation
Ellenbogen K.A., et al. Device Therapy for Congestive Heart Failure. Pennsylvania: Saunders, 2004.
Hayes, D.L, et al. Resynchronization and Defibrillation for Heart Failure: A Practical Approach. UK: Blackwell Publishing, 2004.
S. Goel. Pacing For Patients With Congestive Heart Failure and Dilated Cardiomyopathy www.dcmsonline.org February, 2002/ Jacksonville Medicine
Schwartzman D, Schelbert E, Adelstein E, Gorcsan J, Soman P, Saba S. Image-guided cardiac resynchronization. Europace. 2010 Jun;12(6):877-80. doi: 10.1093/europace/euq103. Epub 2010 Apr 15. — View Citation
Szydlo K, Wita K, Trusz-Gluza M, Urbanczyk D, Filipecki A, Orszulak W, Tabor Z, Krauze J, Kwasniewski W, Myszor J, Turski M, Kolasa J, Szczogiel J. Impact of left ventricular remodeling on ventricular repolarization and heart rate variability in patients after myocardial infarction treated with primary PCI: prospective 6 months follow-up. Ann Noninvasive Electrocardiol. 2008 Jan;13(1):8-13. doi: 10.1111/j.1542-474X.2007.00195.x. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | dP/dt measurements observed during pacing from different left ventricular regions | During the electrophysiology study, the dP/dt measurements will be observed during pacing from different left ventricular regions. | Measurements will be observed at the time of the electrophysiology study (EPS) at enrollment. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 | |
Completed |
NCT02892448 -
Cardiac MRI for Metal on Metal Hip Resurfacing
|
N/A | |
Active, not recruiting |
NCT02537782 -
Myocardial Work and Metabolism in CRT
|
N/A | |
Completed |
NCT02525185 -
Contractile Reserve in Dyssynchrony: A Novel Principle to Identify Candidates for Cardiac Resynchronization Therapy
|
||
Terminated |
NCT01705509 -
The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)
|
N/A | |
Completed |
NCT00999947 -
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
|
N/A | |
Completed |
NCT00626028 -
Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
|
Phase 3 | |
Recruiting |
NCT00138931 -
Genetics of Cardiovascular and Neuromuscular Disease
|
||
Withdrawn |
NCT02838355 -
Employing End Tidal Capnography in Continuous Flow Ventricular Assist Device Patients
|
N/A | |
Completed |
NCT01085955 -
Investigation in Pregnancy Associate Cardiomyopathy
|
N/A | |
Withdrawn |
NCT00428103 -
Effects of Mitral Valve Repair With the Geoform Ring on Cardiomyopathy
|
N/A | |
Recruiting |
NCT00273637 -
Registry and Survey of Women With Pregnancy Related Cardiomyopathy
|
N/A | |
Completed |
NCT00810550 -
Carotid Ultrasound in the Evaluation of Heart Failure
|
N/A | |
Completed |
NCT04603521 -
Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)
|
||
Enrolling by invitation |
NCT03057561 -
Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance
|
N/A | |
Completed |
NCT00027170 -
Technical Development of Cardiovascular Magnetic Resonance Imaging
|
||
Not yet recruiting |
NCT02917395 -
Evaluate the Efficacy of Disopyramide Therapy in Hypertrophic Obstructive Cardiomyopathy Patients
|
N/A | |
Completed |
NCT02331264 -
Cardiac Assessment of Patients With Hip Implants
|
N/A | |
Completed |
NCT02270840 -
Budapest Upgrade CRT Study (Version 009-4.1)
|
N/A | |
Completed |
NCT02164721 -
Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy
|
N/A |